Literature DB >> 30546937

Identification and editing of stem-like cells in methylcholanthrene-induced sarcomas.

Emilie T E Gross1, Carlos D Peinado1, Yujin Jung1, Semi Han1, Beichen Liu1, Endi K Santosa1, Jack D Bui1.   

Abstract

The cancer stem cell (CSC) paradigm posits that specific cells within a tumor, so-called CSC-like cells, have differing levels of tumorigenicity and chemoresistance. Original studies of CSCs identified them in human cancers and utilized mouse xenograft models to define the cancer initiating properties of these cells, thereby hampering the understanding of how immunity could affect CSCs. Indeed, few studies have characterized CSCs in the context of cancer immunoediting, and it is currently not clear how immunity could impact on the levels or stem-like behavior of CSCs. Using the well-studied 3'methylcholanthrene (MCA) model of primary sarcoma formation, we have defined a CSC-like population within MCA-induced sarcomas as expressing high levels of stem cell antigen-1 (Sca-1) and low levels of CD90. These Sca-1+CD90- CSC-like cells had higher tumor initiating ability, could spontaneously give rise to Sca-1-negative cells, and formed more sarcospheres than corresponding non-CSC-like cells. Moreover, when examining MCA-induced sarcomas that were in the equilibrium phase of cancer growth, higher levels of CSC-like cells were found compared to MCA-induced sarcomas in the escape phase of cancer progression. Notably, CSC-like cells also emerged during escape from anti-PD-1 or anti-CTLA4 therapy, thus suggesting that CSC-like cells could evade immune therapy. Finally, we demonstrate that paradoxically, interferon (IFN)-γ produced in vivo by immune cells could promote the emergence of CSC-like cells. Our findings define the existence of a Sca1+CD90- CSC-like population in the MCA-sarcoma model capable of differentiation, tumorsphere formation, and increased tumor initiation in vivo. These cells may also act as mediators of immune resistance during cancer immunoediting and immune therapy.

Entities:  

Keywords:  MCA Sarcoma; cancer immune surveillance; cancer immunoediting; cancer stem cells; immune therapy

Year:  2018        PMID: 30546937      PMCID: PMC6287773          DOI: 10.1080/2162402X.2017.1404212

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  56 in total

Review 1.  The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute.

Authors:  Jilong Yang; Zhiwu Ren; Xiaoling Du; Mengze Hao; Wenya Zhou
Journal:  Stem Cell Investig       Date:  2014-10-27

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Interleukin-17D mediates tumor rejection through recruitment of natural killer cells.

Authors:  Timothy O'Sullivan; Robert Saddawi-Konefka; Emilie Gross; Miller Tran; Stephen P Mayfield; Hiroaki Ikeda; Jack D Bui
Journal:  Cell Rep       Date:  2014-05-01       Impact factor: 9.423

Review 4.  Concise review: stem cell antigen-1: expression, function, and enigma.

Authors:  Christina Holmes; William L Stanford
Journal:  Stem Cells       Date:  2007-03-22       Impact factor: 6.277

5.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

6.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

Review 7.  Immune-mediated dormancy: an equilibrium with cancer.

Authors:  Michele W L Teng; Jeremy B Swann; Catherine M Koebel; Robert D Schreiber; Mark J Smyth
Journal:  J Leukoc Biol       Date:  2008-05-30       Impact factor: 4.962

8.  Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas.

Authors:  Arnout G Schepers; Hugo J Snippert; Daniel E Stange; Maaike van den Born; Johan H van Es; Marc van de Wetering; Hans Clevers
Journal:  Science       Date:  2012-08-01       Impact factor: 47.728

9.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

10.  Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.

Authors:  Christian Schürch; Carsten Riether; Michael A Amrein; Adrian F Ochsenbein
Journal:  J Exp Med       Date:  2013-02-11       Impact factor: 14.307

View more
  2 in total

Review 1.  Targeting Cancer Stem Cells through Epigenetic Modulation of Interferon Response.

Authors:  Jau-Ling Huang; Si-Yun Chen; Chang-Shen Lin
Journal:  J Pers Med       Date:  2022-04-01

Review 2.  Emerging trends in immunotherapy for pediatric sarcomas.

Authors:  Kyle A Dyson; Brian D Stover; Adam Grippin; Hector R Mendez-Gomez; Joanne Lagmay; Duane A Mitchell; Elias J Sayour
Journal:  J Hematol Oncol       Date:  2019-07-16       Impact factor: 17.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.